

**Editor**

Josef S Smolen

**Associate Editors**

Francis Berenbaum  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Kimme Hyrich  
Rik Lories  
Iain McInnes  
Thomas Pap  
David Pisetsky  
Désirée van der Heijde  
Kazuhiko Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 3655 5889  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)

**Disclaimer:** The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

**Copyright:** © 2021 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

*ARD* is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases*, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

**Editorial**

- 1503** Towards clinical significance of the *MUC5B* promoter variant and risk of rheumatoid arthritis-associated interstitial lung disease  
*J A Sparks*

**Viewpoint**

- 1505** Nothing about us without us: involving patient collaborators for machine learning applications in rheumatology  
*S J W Shoop-Worrall, K Cresswell, I Bolger, B Dillon, K L Hyrich, N Geifman, Members of the CLUSTER consortium*

**Review**

- 1511** Axial spondyloarthritis  
*V Navarro-Compán, A Sepriano, B El-Zorkany, D van der Heijde*

**Rheumatoid arthritis**

- 1522** Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naïve patients with rheumatoid arthritis  
*A J Ocon, G Reed, D A Pappas, J R Curtis, J M Kremer*

- 1530** Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in *MUC5B* mutation carriers  
*A Palomäki, FinnGen Rheumatology Clinical Expert Group, A Palotie, J Koskela, K K Eklund, M Pirinen, FinnGen, S Ripatti, T Laitinen, N Mars*

- 1537** B cell depletion impairs vaccination-induced CD8<sup>+</sup> T cell responses in a type I interferon-dependent manner  
*T Graalmann, K Borst, H Manchanda, L Vaas, M Bruhn, L Graalmann, M Koster, M Verboom, M Hallensleben, C A Guzmán, G Sutter, R E Schmidt, T Witte, U Kalinke*

**Inflammatory arthritis**

- 1545** Impaired fertility in men diagnosed with inflammatory arthritis: results of a large multicentre study (iFAME-Fertility)  
*L F Perez-García, E Röder, R J Goekoop, J M W Hazes, M R Kok, H T W Smeele, I Tchvetrikov, A H M van der Helm-van Mil, J H van der Kaap, P Kok, B P Krijthe, R J E M Dolhain*

**Psoriatic arthritis**

- 1553** Role of ultrasound for assessment of psoriatic arthritis patients with fibromyalgia  
*A Polacheke, V Furer, M Zureik, S Nevo, L Mendel, D Levartovsky, J Wollman, V Aloush, R Tzemach, O Elalouf, M Anouk, M Berman, I Kaufman, O Carmi, Y Lahat, T Eviatar, H Padova, H Sarbagil-Maman, S Borok, A Broyde, L Eder, D Paran, O Elkayam*
- 1559** Ex vivo mass cytometry analysis reveals a profound myeloid proinflammatory signature in psoriatic arthritis synovial fluid  
*N Yager, S Cole, A Lledo Lara, A Maroof, F Penkava, J C Knight, P Bowness, H Al-Mossawi*

**Systemic lupus erythematosus**

- 1568** Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity  
*D Jesus, M Larosa, C Henriques, A Matos, M Zen, P Tomé, V Alves, N Costa, V Le Guern, L Iaccarino, N Costedoat-Chalumeau, A Doria, L S Inês*
- 1575** Metagenome-wide association study revealed disease-specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese  
*Y Tomofuji, Y Maeda, E Oguro-Igashira, T Kishikawa, K Yamamoto, K Sonehara, D Motooka, Y Matsumoto, H Matsuoka, M Yoshimura, M Yagita, T Nii, S Ohshima, S Nakamura, H Inohara, K Takeda, A Kumanoogoh, Y Okada*

MORE CONTENTS ►



EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008  
JM00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

## Systemic sclerosis

**1584** Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis

*K E N Clark, C Campochiaro, E Csomor, A Taylor, K Nevin, N Galwey, M A Morse, J Singh, Y V Teo, V H Ong, E Derrett-Smith, N Wisniacki, S M Flint, C P Denton*

**1594** TGF $\beta$  promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis



*P Laurent, B Allard, P Manicki, V Jolivel, E Levionnois, M Jeljeli, P Henrot, J Izotte, D Leleu, A Groppi, J Seneschal, J Constans, C Chizzolini, C Richez, P Duffau, E Lazaro, E Forcade, T Schaevebeke, T Pradeu, F Batteux, P Blanco, C Contin-Bordes, M-E Truchetet*

## Crystal arthritis

**1604** Mechanosensitive TRPV4 is required for crystal-induced inflammation

*Z Lan, L Chen, J Feng, Z Xie, Z Liu, F Wang, P Liu, X Yue, L Du, Y Zhao, P Yang, J Luo, Z Zhu, X Hu, L Cao, P Lu, R Sah, K Lavine, B Kim, H Hu*

## Osteoarthritis

**1615** 14-3-3 epsilon is an intracellular component of TNFR2 receptor complex and its activation protects against osteoarthritis

*W Fu, A Hettinhouse, Y Chen, W Hu, X Ding, M Chen, Y Ding, J Mundra, W Song, R Liu, Y-S Yi, M Attur, J Samuels, E Strauss, P Leucht, R Schwarzkopf, C Liu*

## Letters

**1628** Early reduction in circulating monocyte count predicts maintenance of remission in patients with rheumatoid arthritis treated with anti-TNF therapy

*M R A Shipa, R Amarnani, S-A Yeoh, M D Mainuddin, M R Ehrenstein*

**1629** Nail involvement in psoriatic arthritis patients is an independent risk factor for carotid plaque

*I J Colunga-Pedraza, D A Galarza-Delgado, J R Azpiri-Lopez, A B Rodriguez-Romero, N Guajardo-Jauregui, J A Cardenas-de la Garza, S Lugo-Perez, A Meza-Garza, J Loya-Acosta, A C Garza-Acosta*

**1631** Tofacitinib for the treatment of antineutrophil cytoplasm antibody-associated vasculitis: a pilot study

*Y Liu, Z Ji, W Yu, S Wu, H Chen, L Ma, Z Ding, L Jiang*

**1633** Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA's Adverse Event Reporting System



*M Pistor, A G F Hoepner, Y Lin, S Jung, C L Bassetti, A Chan, A Salmen, R Hoepner*

**1635** Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis

*S Bugatti, L De Stefano, S Balduzzi, M I Greco, T Luvaro, I Cassaniti, L Bogliolo, I Mazzucchelli, B D'Onofrio, M di Lernia, E Mauric, D Lillieri, F Baldanti, A Manzo, C Montecucco*

**1638** Unexpected impact of COVID-19 lockdown on spinal mobility and health perception in spondyloarthritis

*S De Mits, A-S De Craemer, L Deroo, T Renson, F E Van den Bosch, P Carron, D Elewaut*

## Electronic pages

**e188** European League against Rheumatism/ American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist's point of view

*M Infantino, M Manfredi, N Bizzaro, On behalf of the Study Group on Autoimmune Diseases of the Italian Society of Clinical Pathology and Laboratory Medicine*

**e189** Response to: 'European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist's point of view' by Infantino *et al*

*M Aringer, K H Costenbader, T Dörner, S R Johnson*

**e190** New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion

*K Sacre, L Delaval, A Dossier, J-F Alexandra, M Berleur, M-P Chauveheid, G Ducrocq, T Goulenok, D van Gysel, D Rouzaud, T Papo*

**e191** Response to: 'New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion' by Sacre *et al*

*M Aringer, K Costenbader, T Dörner, S R Johnson*

- e192** Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus  
*B Wang, S Chen, Q Zheng, Z Gao, R Chen, J Xuan, Y Liu, G Shi*
- e193** Response to: 'Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus' by Wang *et al*  
*M Aringer, K Costenbader, T Dörner, S R Johnson*
- e194** NCF1-339 polymorphism and systemic lupus erythematosus  
*B Joob, V Wiwanitkit*
- e195** Response to: 'NCF1-339 polymorphism and systemic lupus erythematosus' by Joob and Wiwanitkit  
*C P Linge, A Bengtsson*
- e196** Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors  
*A Meyer, P S Witekkind, K Kotschenreuther, J Schiller, J von Tresckow, T H Haak, D M Kofler*
- e197** Response to: 'Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors' by Meyer *et al*  
*M Rosenzwajg, R Lorenzon, D Klatzmann*
- e198** Correspondence to 'Slope sign': a feature of large vessel vasculitis?  
*M Milchert, M Brzosko, A Bull Haaversen, A P Diamantopoulos*
- e199** Response to: 'Correspondence to 'Slope sign': a feature of large vessel vasculitis?' by Milchert *et al*  
*A Sebastian, A Kayani, B Dasgupta*
- e200** Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flares  
*A M Didierlaurent, C Dessart, A L Cunningham*
- e201** Response to: 'Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flares' by Didierlaurent *et al*  
*C Yokose, H Choi*
- e202** Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care  
*K Parperis*
- e203** Response to: 'Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care' by Parperis *et al*  
*E Roddy, C D Mallen, on behalf of the CONTACT trial authors*
- e204** Association between osteoporosis and statins therapy: the story continues  
*A M Burden, S Weiler*
- e205** Response to: 'Association between osteoporosis and statin therapy: the story continues' by Burden and Weiler  
*M Leutner, C Matzhold, L Bellach, C Deisinger, J Harreiter, S Thurner, P Klimek, A Kautzky-Willer*